Semanteon Capital Management LP Acquires New Shares in Guardant Health, Inc. $GH

Semanteon Capital Management LP bought a new position in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 9,097 shares of the company’s stock, valued at approximately $568,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Allworth Financial LP boosted its stake in shares of Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after buying an additional 552 shares during the last quarter. Sound Income Strategies LLC bought a new stake in shares of Guardant Health during the 3rd quarter valued at $38,000. Smartleaf Asset Management LLC increased its stake in shares of Guardant Health by 162.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock worth $68,000 after purchasing an additional 678 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in Guardant Health by 99.4% in the 2nd quarter. SBI Securities Co. Ltd. now owns 1,366 shares of the company’s stock worth $71,000 after purchasing an additional 681 shares during the period. Finally, Bayforest Capital Ltd purchased a new position in Guardant Health during the third quarter valued at $78,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GH. UBS Group reiterated a “buy” rating and set a $175.00 price objective on shares of Guardant Health in a research note on Friday, January 30th. Leerink Partners increased their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday. Robert W. Baird assumed coverage on Guardant Health in a research report on Tuesday. They issued an “outperform” rating and a $120.00 price objective on the stock. Barclays reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Guardant Health in a report on Friday. Finally, Wells Fargo & Company boosted their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average target price of $117.43.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Insider Activity

In other Guardant Health news, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the sale, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. The trade was a 37.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 434,511 shares of company stock worth $45,580,887. 6.10% of the stock is owned by insiders.

Guardant Health Price Performance

NASDAQ:GH opened at $103.10 on Friday. The company has a market cap of $12.99 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The stock’s 50 day simple moving average is $106.69 and its two-hundred day simple moving average is $86.22.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. During the same quarter in the previous year, the company earned ($0.62) EPS. The business’s revenue was up 39.4% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.